Neoadjuvant FinHer regimen in patients with HER2-positive breast cancer: a retrospective audit - Top-Institutions - MDSpire

Neoadjuvant FinHer regimen in patients with HER2-positive breast cancer: a retrospective audit

  • By

  • Anoop T. M.

  • Rona Joseph

  • Sherin Mathew

  • Mintu Mathew

  • Saikumar Soman

  • Kalai Bharathi

  • Senthamizhan S

  • May 18, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Regional Cancer Centre, Thiruvananthapuram
    Regional Cancer Centre, Thiruvananthapuram

    Thiruvananthapuram, Kerala

    Key Differentiators

    • Oncology

  • #2

    The Cancer Institute Hospital of Japanese Foundation for Cancer Research
    The Cancer Institute Hospital of Japanese Foundation for Cancer Research

    Tokyo, Tokyo

    Key Differentiators

    • Oncology

  • #3

    University Hospital Centre Zagreb
    University Hospital Centre Zagreb

    Zagreb, Zagreb

    Key Differentiators

    • Oncology

  • #4

    University of Padua
    University of Padua

    Padua, Veneto

    Key Differentiators

    • Oncology

  • #5

    National Surgical Adjuvant Breast and Bowel Project
    National Surgical Adjuvant Breast and Bowel Project

    N/A, N/A

    Key Differentiators

    • Oncology

Original Source(s)

Neoadjuvant FinHer regimen in patients with HER2-positive breast cancer: a retrospective audit

  • by Anoop T. M., Rona Joseph, Sherin Mathew, Mintu Mathew, Saikumar Soman, Kalai Bharathi, Senthamizhan S

  • May 18, 2026

Related Content

Synthetic short RNA in cancer

Ultra-high-sensitivity next-generation sequencing–based MRD predicts outcome in intensively treated older patients with acute myeloid leukemia: results from the ALFA-1200 cohort

Treatment evolution and survival impact of consolidation therapies in mantle cell lymphoma: insights from an Asia-Pacific real-world registry